Cannabinol β-O-Glucoside Inhibitors of the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson’s Disease
Computer analyses supported its Keap1-targeting activity, identifying CS-11 as a promising Parkinson’s disease therapeutic candidate and showing the strongest neuroprotective effect in a Parkinson’s disease model.